Don't settle for an antibiotic that's only 50% as effective. Look at study data to see how this can cost more in the long run.
When evaluating antimicrobials for control and treatment of bovine respiratory disease (BRD), you probably start by comparing product labels. You evaluate bacterial pathogens treated or controlled, duration, withdrawal times and cost. But there’s one more important factor: the research data behind the label.
That means data from unbiased study trials, including the product’s first-treatment efficacy, how often re-treatments are needed, whether the product duration has been proven and long-term costs. These kinds of results provide a good indication of how antimicrobials work in real-life situations and can help you select the best one for your operation.
What does all this mean?
Since DRAXXIN required fewer re-treatments and resulted in decreased mortality and fewer chronic animals than other antimicrobials:
- There’s a greater likelihood of first-treatment success.
- Cattle can get back to health and productivity faster.
- Overall cattle health and well-being may improve.
- There are fewer treatment and labor costs.
- You may realize greater net income with reduced death loss.
- It supports responsible use of antibiotics.
Each of the trials was conducted by universities or professional contract research firms, and all of the results and conclusions have been published in refereed journals. We have confidence in the results and encourage veterinarians and producers to ask questions to better understand how a trial was run to ensure you trust the data behind the product, too.
IMPORTANT SAFETY INFORMATION: DRAXXIN has a pre-slaughter withdrawal time of 18 days in cattle. Do not use in female dairy cattle 20 months of age or older. Do not use in animals known to be hypersensitive to the product. Full Prescribing Information.
- Data on file, Study Report Nos. 1133R-60-05-491, A131R-US-12-028, 2132T-60-01-050, 1133R-60-02-376, 2132T-60-01-063, 1133R-60-03-388 and 11RGDRA01, Zoetis Inc. ↵
- Data on file, Study Report Nos. 1133R-60-05-491, 1133R-60-05-492, 1133R-60-05-493, A131R-US-12-028, 2132T-60-01-050, 1133R-60-02-376, 2132T-60-01-063 and 1133R-60-03-388, Zoetis Inc. ↵